Key result
The interplay between platelet activation and coagulation pathways drives fibrin clot formation, supporting the clinical benefit of combination therapy in secondary cardiovascular disease prevention.
The interplay between platelet activation and coagulation pathways is crucial in thrombus formation, providing a mechanistic rationale for combination therapies in secondary cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Mechanistic rationale supports dual pathway inhibition in secondary prevention; leaves open optimal regimens and net benefit in trials.
Swieringa et al. (2018) conducted a review in Thrombus formation. The interplay between platelet activation and coagulation pathways drives fibrin clot formation, supporting the clinical benefit of combination therapy in secondary cardiovascular disease prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: